Quote this publication Share Print

LORAMYC

-
Opinions on drugs - Posted on Feb 15 2010

Reason for request

Inclusion on the list of medicines approved by National Insurance and approved for hospital use.

-


Clinical Benefit

Substantial

The actual benefit provided by LORAMYC in the treatment of oropharyngeal candidiasis in immunocompromised patients, in particular patients with upper aerodigestive tract cancer after radiotherapy and in HIV infected patients is substantial.


Clinical Added Value

no clinical added value

LORAMYC, a muco-adhesive buccal tablet containing miconazole, does not provide improvement in actual benefit compared to miconazole oral gel (IAB V).

Nevertheless, the Committee emphasizes that this new pharmaceutical formulation represents a useful treatment option for patients.


Contact Us

Évaluation des médicaments
All our publications